AirFluSal Forspiro

AirFluSal Forspiro is a combination pharmaceutical product used for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It contains salmeterol and fluticasone propionate, effectively acting as a generic or biosimilar alternative to established brands like Seretide. The product is administered via the Forspiro device, which is an innovative dry powder inhaler designed for ease of use and dosage tracking.

The brand is a flagship offering from Sandoz, a global leader in generic pharmaceuticals and biosimilars. Originally a division of the Swiss multinational Novartis, Sandoz became an independent, publicly traded company following a spin-off in 2023. This transition allowed Sandoz to focus exclusively on its mission to increase patient access to high-quality affordable medicines.

Manufacturing of AirFluSal Forspiro takes place across multiple locations within Sandoz's global supply chain, often involving specialized facilities in Europe and Asia to ensure rigorous quality standards. The brand represents a significant portion of Sandoz's respiratory portfolio, catering to a global market with a headquarter presence in Switzerland.